University of Baghdad

uobaghdad.edu.iq

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

160

Active

53

Phase 3

11

Total enrollment

11,053

Pipeline matrix

Showing 14 of 14 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Chlorzoxazone1
Orphenadrine Citrate1
Non surgical root surface debridement in one stage with receiving Ibuprofen1
Resveratrol-Based Mouthwash1
Chlorhexidine Gluconate 0.12 % Mouthwash1
Acetaminophen1
Local melatonin powder1
Suprachoroidal triamcinolone acetonide1
Mirror Therapy plus Soft Robotic Glove1
Metformin gel, 1%1
Microneedling + Injectable Hyaluronic Acid1
Standard-dose rhBMP-21
Micro-dose rhBMP-21
Sterile Normal Saline1

Next readouts

  • 2025-06-01
  • 2025-08-01
  • 2025-09-30
  • 2026-04
  • 2026-05
  • 2026-06
  • 2026-09
  • 2026-09-17
  • 2027-03-09
  • 2028-03

Top conditions

  • Periodontitis13
  • Periodontal Diseases8
  • Orthodontic Appliance Complication6
  • Impacted Third Molar Tooth4
  • Plaque Induced Gingivitis4
  • Dental Implant4
  • Tooth Position Anomalies3
  • Root Resorption3

Frequently asked questions about University of Baghdad

How many clinical trials does University of Baghdad have on ClinicalTrials.gov?
University of Baghdad is listed as the lead sponsor on 160 clinical trials in ClinicalTrials.gov, 53 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Baghdad's trials are in Phase 3?
11 of University of Baghdad's trials are in Phase 3, spread across 14 active drug programs.
What therapeutic areas does University of Baghdad focus on?
University of Baghdad's most-studied conditions on ClinicalTrials.gov are Periodontitis, Periodontal Diseases, Orthodontic Appliance Complication, Impacted Third Molar Tooth, Plaque Induced Gingivitis.
When are University of Baghdad's next clinical trial readouts?
University of Baghdad has 10 upcoming primary-completion readouts tracked here; the soonest is “Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon”, expected around 2025-06-01.